Citigroup’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-5,000
Closed -$150K 6585
2022
Q1
$150K Buy
+5,000
New +$135K ﹤0.01% 4225
2020
Q4
Sell
-1,050
Closed -$25K 7587
2020
Q3
$25K Buy
1,050
+660
+169% +$16.2K ﹤0.01% 6032
2020
Q2
$7K Buy
+390
New +$7.02K ﹤0.01% 7184
2020
Q1
Sell
-170
Closed -$4K 7752
2019
Q4
$4K Sell
170
-50
-23% -$1.03K ﹤0.01% 7460
2019
Q3
$4K Sell
220
-160
-42% -$3.31K ﹤0.01% 7403
2019
Q2
$10K Sell
380
-120
-24% -$2.71K ﹤0.01% 7311
2019
Q1
$13K Sell
500
-130
-21% -$2.97K ﹤0.01% 7152
2018
Q4
$14K Buy
630
+290
+85% +$8.18K ﹤0.01% 7040
2018
Q3
$11K Sell
340
-450
-57% -$13.5K ﹤0.01% 7327
2018
Q2
$22K Sell
790
-190
-19% -$6.76K ﹤0.01% 6873
2018
Q1
$35K Buy
980
+440
+81% +$17.6K ﹤0.01% 6413
2017
Q4
$21K Buy
540
+380
+238% +$14.5K ﹤0.01% 6714
2017
Q3
$4K Sell
160
-150
-48% -$3.65K ﹤0.01% 6907
2017
Q2
$8K Buy
310
+50
+19% +$1.37K ﹤0.01% 6605
2017
Q1
$9K Buy
260
+160
+160% +$4.08K ﹤0.01% 6601
2016
Q4
$2K Buy
+100
New +$2.86K ﹤0.01% 7065

Other funds holding RIGL

Citigroup's RIGL Position: Q2 2026 in Review

Citigroup increased its Rigel Pharmaceuticals (RIGL) stake by 578% in Q2 2026, buying an estimated $856K and bringing the position to 32,566 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3278.

Citigroup first reported a position in RIGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.5M in Q1 2018. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Citigroup held 32,566 shares of Rigel Pharmaceuticals worth $1.27M as of Q2 2026.
  • Citigroup bought 27,765 Rigel Pharmaceuticals shares in Q2 2026, an estimated $856K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3278 holding.
  • Citigroup first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Rigel Pharmaceuticals position peaked at $3.5M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.